Repligen Corporation (NasdaqGS: RGEN)
Health Care · Life Sciences Tools & Services · US
$182.41
+0.71% today · +45.1% 1Y
Repligen Corporation (NasdaqGS: RGEN) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $10.22B and employs 2,000 people.
Over the last twelve months the share price has gained 45.1%, trading between 100.99 and 179.87.
Tweenvest scores Repligen Corporation across four factors: quality 67/100, value 35/100, growth 81/100. Its strongest factor is growth.
RGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.22B
- Revenue (TTM)
- $785.10M
- P/E
- 248.20
- EPS
- 0.73
- Dividend yield
- —
- Beta (5Y)
- 1.01
- 52-week high
- $179.87
- 52-week low
- $100.99
- Avg volume (3M)
- —
- Shares outstanding
- 56.44M
- Employees
- 2,000
- Next earnings
- —
About Repligen Corporation
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
- ISIN
- US7599161095
- Founded
- 1981
- Listed since
- Apr 29, 1986
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $628.06 | -0.19% |
| Danaher CorporationNYSE: DHR | $153.85B | $215.24 | -1.65% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF587.80 | -0.74% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $153.39 | -3.53% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $260.28 | +0.18% |
| Waters CorporationNYSE: WAT | $40.35B | $410.71 | +0.00% |
Figures last refreshed Aug 18, 2026.